Introduction

Since the approval of the first statin in 1987, statin therapy has transformed the landscape of cardio›vascular medicine. Statins were originally developed to lower cholesterol levels and manage hypercholesterolemia; however, they soon proved beneficial for cardiovascular prevention, as elevated cholesterol is a major risk factor for cardiovascular disease. These medications quickly became a cornerstone in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), particularly among patients with diabetes, hypertension, and other cardiovascular risk factors. Statins not only reduce the incidence of heart attacks and strokes but also decrease overall mortality, making them one of the most widely prescribed drug classes in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately 47 million U.S. adults were taking a statin in 2023, emphasizing their widespread use in clinical practice. 

Despite their established benefits in cardiovascular health, concerns have emerged that statins may contribute to neurocognitive decline, such as memory impairment and dementia. Understanding whether these concerns are supported by evidence is critical for pharmacists, who play a central role in medication counseling and patient education. This raises the question: what does the current scientific evidence reveal about statins and cognitive function?

These CDC maps illustrate the prevalence of high cholesterol (above) and heart disease (below) across U.S. counties from 2018 to 2020. The similar geographic patterns highlight the strong association between high cholesterol and increased heart disease risk.

What are Statins?

Statin medications are inhibitors of hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme in the liver, which reduces the synthesis cholesterol. Inhibition of this rate-limiting step effectively lowers total cholesterol, low-density lipoprotein (LDL), and triglyceride levels, thereby reducing the risk of atherosclerotic plaque formation and cardiovascular events. FDA-approved statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, and pitavastatin.

Statins are used to manage a variety of lipid disorders and prevent cardiovascular events. Indications for statin therapy include:

• Primary or mixed hyperlipidemia
• Hypertriglyceridemia
• Familial hypercholesterolemia
• Atherosclerosis
• Primary prevention of ASCVD
• Secondary prevention in patients with clinical ASCVD

In adults without established cardiovascular disease, statins are used to reduce overall cardiovascular risk. Common risk factors and enhancers of ASCVD include: 

• Diabetes mellitus
• Hypertension
• Obesity
• Smoking or tobacco use
• Chronic kidney disease
• Chronic inflammatory conditions
• Metabolic syndrome

In patients with clinical ASCVD, statins are indicated to prevent recurrent cardiovascular events. Conditions classified under clinical ASCVD include:

• Myocardial Infarction
• Stroke or transient ischemic attack
• Coronary artery disease
• Peripheral artery disease
• Post-revascularization

Statins are generally well tolerated. The most commonly reported adverse effects include:

• Musculoskeletal symptoms: myalgia, arthralgia, soreness, fatigue
• Gastrointestinal symptoms: diarrhea, constipation, nausea, flatulence

Rarely, statins may cause liver enzyme elevations or serious rhabdomyolysis, but these events are uncommon.

Understanding Dementia and Cognitive Decline

Dementia is a neurocognitive disorder characterized by progressive decline in memory, thinking, and reasoning, which can significantly impact daily functioning. Currently, Dementia affects an estimated 55 million people worldwide, with this number projected to nearly triple by 2050. As the disease progresses, patients may experience behavioral changes, personality shifts, and increased dependence on caregivers. Below is a table describing the different types of dementia.

Several modifiable risk factors have been identified, including lack of physical activity, uncontrolled diabetes, hypertension, hearing loss, and tobacco or alcohol use. According to the CDC, up to 45% of all dementia cases may be preventable or delayed through lifestyle modification and management of chronic conditions. With the global burden of dementia rising, preventative strategies are critical and understanding the impact of medications such as statins on cognitive health is an important aspect of care.

Historical Concerns About Statins and Cognition

Now that we delved into the many features of statins and dementia, where did the growing fear that statins might cause dementia originate from? A couple of factors contributed. 

First, in 2012, the FDA issued a safety communication regarding potential cognitive effects of statin therapy. The communication noted that memory loss and confusion had been reported, but emphasized that these cognitive side effects were minor and reversible upon discontinuation of therapy. 

Second, public concern is fueled by a common misconception about the brain’s dependence on cholesterol. Some worry that lowering blood cholesterol with statins could harm brain function, but that is not supported by physiology. Although it is true that the brain relies on cholesterol for proper function, the brain synthesizes its own cholesterol independently of blood cholesterol levels through the central nervous system. Early case reports and small observational studies also suggested a possible link between statin use and cognitive changes, which further amplified public concern. 

Given these factors, it is understandable why some patients and clinicians may perceive a connection between statin therapy and dementia. But what does the scientific evidence actually show? To answer this, we can turn to a recent systematic review and meta-analysis from 2025 to examine the most recent evidence on this topic.

What Does the Evidence Say?

A 2025 systematic review and meta-analysis analyzed data from 55 observational studies including over 7 million participants to investigate whether statin use is associated with dementia risk. The analysis found that statin therapy was associated with a statistically significant reduction in the risk of all-cause dementia, effectively refuting the misconception that statins negatively impact cognitive function. Among individual statins, rosuvastatin showed one of the strongest associations with reduced dementia risk. 

Several potential mechanisms have been proposed to explain the neuroprotective effects of statins:

Despite these findings, the 2012 safety communication regarding cognitive effects of statins remains relevant. Statins can occasionally cause temporary cognitive changes, such as memory lapses or “mental fuzziness”. These events are rare, generally mild, and reversible upon discontinuation of statin therapy. A proposed mechanism involves reduced coenzyme Q10 (ubiquinone) levels, as statins inhibit the pathway responsible for its synthesis. Since coenzyme Q10 is essential for mitochondrial energy production, temporary reductions may lead to mild cognitive symptoms in some individuals. Importantly, these effects do not indicate permanent dementia.

Implication for Pharmacists and Patients

Pharmacists play a key role in the community by providing medication counseling and education. This puts pharmacists in a unique position to address common misconceptions related to medications and to give peace of mind to patients who may worry about initiating statin drugs. When addressing patient concerns about statin therapy and cognition, key counseling points include:

• Emphasizing that serious or permanent cognitive impairment is not associated with statin use
• Explaining that temporary memory lapses are rare side effects of statins, but are not serious and reversible
• Highlighting that statins have cardiovascular and potential neuroprotective benefits 
• Encouraging adherence statin therapy to maximize long-term health outcomes

Patient education should also include lifestyle interventions to reduce both cardiovascular and dementia risk, such as regular exercise, blood pressure control, diabetes management, and avoidance of tobacco or alcohol.

Conclusion

Statins remain a cornerstone for cardiovascular health and are generally safe and well tolerated medications. While public concern has emerged regarding potential cognitive effects, evidence shows that statin use is not associated with an increased risk of dementia and may actually provide neuroprotective benefits. Several potential mechanisms have been proposed to explain these effects, though further research is needed to clarify the exact pathways by which statins influence brain health. Temporary cognitive changes are rare, mild, and reversible and do not outweigh the substantial cardiovascular and potential neurocognitive benefits of therapy. For pharmacists, understanding this evidence is critical for patient counseling, addressing misconceptions, and promoting adherence to ensure that patients receive the full spectrum of benefits statins offer. 

APPE student, Hailey Montour

References

Alzheimer’s Society (UK). Types of Dementia. Accessed February 24, 2026. https://www.alzheimers.org.uk/about-dementia/types-dementia

American Heart Association. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000678

Atrium Health. The facts about statins and dementia risk. Accessed February 24, 2026. https://www.atria.org/education/the-facts-about-statins-and-dementia-risk/

Bays HE, Taub PR, Epstein E, et al. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol. 2021;5:100149. Published 2021 Jan 23. doi:10.1016/j.ajpc.2021.100149

Centers for Disease Control and Prevention. Alzheimer’s Disease and Preventing Cognitive Decline. Accessed February 24, 2026. https://www.cdc.gov/alzheimers-dementia/prevention/index.html

Centers for Disease Control and Prevention. Cholesterol Facts & Statistics. Updated 2023. Accessed February 24, 2026. https://www.cdc.gov/cholesterol/data-research/facts-stats/index.html

Centers for Disease Control and Prevention. What is dementia? Updated March 2024. Accessed February 24, 2026.

Available at: https://www.cdc.gov/alzheimers-dementia/about/index.html

Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-493. doi:10.2183/pjab.86.484

Sizar O, Khare S, Patel P, et al. Statin Medications. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; Updated February 29, 2024. Accessed February 24, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430940/

U.S. Food and Drug Administration. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol‑Lowering Statin Drugs. Accessed February 24, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs

van Vliet P. Cholesterol and late-life cognitive decline. J Alzheimers Dis. 2012;30 Suppl 2:S147-S162. doi:10.3233/JAD-2011-111028

Westphal Filho FL, Moss Lopes PR, Menegaz de Almeida A, et al. Statin use and dementia risk: A systematic review and updated meta-analysis. Alzheimers Dement (N Y). 2025;11(1):e70039. Published 2025 Jan 16. doi:10.1002/trc2.70039